125 related articles for article (PubMed ID: 16305731)
1. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine.
Duley JA; Chocair PR; Florin TH
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1161-2. PubMed ID: 16305731
[No Abstract] [Full Text] [Related]
2. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
3. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
4. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
5. A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain.
Egan LJ
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):170-1. PubMed ID: 17296527
[No Abstract] [Full Text] [Related]
6. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
Roberts RL; Gearry RB; Barclay ML
Pharmacogenomics; 2010 Nov; 11(11):1505-8. PubMed ID: 21121769
[No Abstract] [Full Text] [Related]
9. If at first you don't succeed...Try again?
Kane S
Am J Gastroenterol; 2001 Jul; 96(7):2260. PubMed ID: 11467666
[No Abstract] [Full Text] [Related]
10. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
[TBL] [Abstract][Full Text] [Related]
11. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab M; Herrlinger K; Schaeffeler E; Stange EF
Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
[No Abstract] [Full Text] [Related]
13. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
Min MX; Weinberg DI; McCabe RP
J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
[TBL] [Abstract][Full Text] [Related]
15. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
16. [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Cha JM; Kim HJ
Korean J Gastroenterol; 2008 May; 51(5):319-22. PubMed ID: 18516018
[No Abstract] [Full Text] [Related]
17. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Su C; Lichtenstein GR
Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
Seinen ML; de Boer NK; Smid K; van Asseldonk DP; Bouma G; van Bodegraven AA; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1085-90. PubMed ID: 22132961
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
Nguyen TV; Nguyen TM; Lachaux A; Boulieu R
J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979
[TBL] [Abstract][Full Text] [Related]
20. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
Derijks LJ; Gilissen LP; de Boer NK; Mulder CJ
J Hepatol; 2006 Apr; 44(4):821-2. PubMed ID: 16487623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
